Prevalence of Hepatitis C Antibodies (HCV) in a Dialysis Population at One Center | Zendy

Selgas Rafael | Zendy; Martinez-Zapico Rosa | Zendy; Bajo M. Auxiliadora | Zendy; Romero Jose Ramon | Zendy; Munoz Jesus | Zendy; Ri Carmen | Zendy; Miranda Blanca | Zendy; Miguel Jose Luis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prevalence of Hepatitis C Antibodies (HCV) in a Dialysis Population at One Center

Author(s) -

Selgas Rafael,

Martinez-Zapico Rosa,

Bajo M. Auxiliadora,

Romero Jose Ramon,

Munoz Jesus,

Ri Carmen,

Miranda Blanca,

Miguel Jose Luis

Publication year - 1992

Publication title -

peritoneal dialysis international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.79

H-Index - 83

eISSN - 1718-4304

pISSN - 0896-8608

DOI - 10.1177/089686089201200106

Subject(s) - medicine , hemodialysis , continuous ambulatory peritoneal dialysis , hepatitis c virus , dialysis , antibody , peritoneal dialysis , hepatitis c , population , ambulatory , blood transfusion , gastroenterology , immunology , virus , environmental health

Hepatitis C (HC) has been recently diagnosed by determination of specific antibodies that represent the former so-called non-A, non-B hepatitis. We studied the prevalence of plasma HCV antibodies among 61 unselected patients on hemodialysis (HD) and 43 on continuous ambulatory peritoneal dialysis (CAPD). Plasma C-antibodies were determined through the ELISA test system. Transfusion policy was the same in both groups. The prevalence of hepatitis C virus antibodies was significantly higher in hemodialysis patients than among those on CAPD. Time on dialysis, previous blood transfusions, and renal transplantation seem to increase the prevalence of C hepatitis antibodies among hemodialy sis patients. The effect of these parameters on CAPD was smaller. Understanding the reasons for these differences may help prevent this disease among dialysis patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research